PharmaCyte Biotech Inc (PMCB)

[xxxWEEMANxxx]

NEWS!!! PharmaCyte May Be On the Verge of a Major Breakthrough in the Treatment of Diabetes

BALTIMORE, MD / ACCESSWIRE / November 3, 2015 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research update on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research update, along with disclosures and disclaimers, or to download it and previous reports, updates, and articles in their entirety, please visit www.GoldmanResearch.com.

In the update, analyst Rob Goldman notes that the Company's approach to diabetes therapy could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes, and could potentially replace them.

According to Goldman, "Last week, PharmaCyte held the 2nd annual meeting of its International Diabetes Consortium to review data that has been generated by the Consortium and update its strategic plan for the development of PMCB's treatment for insulin dependent diabetes. With the review now complete we believe management will soon provide investors with a R&D roadmap for its diabetes treatment, taking the stock past a key daily moving average (DMA.) Plus, with November serving as Diabetes Awareness Month, an update on its diabetes research progress will draw substantial attention from major players and funders in diabetes research."

"The two key components of PharmaCyte's treatment for Type 1 diabetes are Melligen cells and the Cell-in-a-Box(R) technology. Melligen cells have been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. PharmaCyte's plan is to encapsulate those live cells and then implant the capsules into a patient with diabetes to act as an "artificial" pancreas, thereby eliminating the need for insulin injections," noted Goldman."

Goldman continued, "Demonstrating the ability to eliminate the need for insulin injections for millions of sufferers through soon-to-be launched next stage studies could be the driver to take these shares to a new 52-week high."

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on PharmaCyte Biotech, Inc. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from PharmaCyte Biotech Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com. In 2015, Goldman Small Cap Research has been compensated by a third party in the amount of $22,000 for investment research services that includes the publication of research reports, updates, and a series of articles.

About PharmaCyte Biotech.: PharmaCyte Biotech Inc. (OTCQB - PMCB) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box(R). This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. More information on PMCB can be found at www.PharmaCyteBiotech.com.

Goldman Small Cap Research